JP2008502323A - コブラ毒因子様機能を有するヒト補体ｃ３誘導体 - Google Patents

コブラ毒因子様機能を有するヒト補体ｃ３誘導体 Download PDF

Info

Publication number
JP2008502323A
JP2008502323A JP2007511077A JP2007511077A JP2008502323A JP 2008502323 A JP2008502323 A JP 2008502323A JP 2007511077 A JP2007511077 A JP 2007511077A JP 2007511077 A JP2007511077 A JP 2007511077A JP 2008502323 A JP2008502323 A JP 2008502323A
Authority
JP
Japan
Prior art keywords
protein
modified
cvf
complement
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007511077A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008502323A5 (enExample
Inventor
カール−ウィルヘルム フォーゲル，
デイビッド シー． フリッジンガー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Hawai'i at Hilo
Original Assignee
University of Hawai'i at Hilo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Hawai'i at Hilo filed Critical University of Hawai'i at Hilo
Publication of JP2008502323A publication Critical patent/JP2008502323A/ja
Publication of JP2008502323A5 publication Critical patent/JP2008502323A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
JP2007511077A 2004-04-30 2005-04-29 コブラ毒因子様機能を有するヒト補体ｃ３誘導体 Pending JP2008502323A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US56706904P 2004-04-30 2004-04-30
US65324705P 2005-02-14 2005-02-14
US66735205P 2005-03-31 2005-03-31
PCT/US2005/015119 WO2005107785A2 (en) 2004-04-30 2005-04-29 Human complement c3 derivates with cobra venom factor-like function

Publications (2)

Publication Number Publication Date
JP2008502323A true JP2008502323A (ja) 2008-01-31
JP2008502323A5 JP2008502323A5 (enExample) 2008-05-29

Family

ID=35320733

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007511077A Pending JP2008502323A (ja) 2004-04-30 2005-04-29 コブラ毒因子様機能を有するヒト補体ｃ３誘導体

Country Status (9)

Country Link
US (2) US8632780B2 (enExample)
EP (1) EP1755658A4 (enExample)
JP (1) JP2008502323A (enExample)
KR (1) KR20070036057A (enExample)
AU (1) AU2005240096A1 (enExample)
CA (1) CA2565227A1 (enExample)
IL (1) IL178905A0 (enExample)
MX (1) MXPA06012321A (enExample)
WO (1) WO2005107785A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017519049A (ja) * 2014-06-12 2017-07-13 ユニヴァーシティ オブ ハワイＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｈａｗａｉｉ 免疫原性を低減するかまたは予防するためのヒト化コブラ毒因子の使用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005003159A1 (en) 2003-07-03 2005-01-13 Koeln Johanna Complement depletion using recombinant human c3-derivatives
MXPA06012321A (es) 2004-04-30 2007-04-19 Univ Hawaii Derivados c3 del complemento humano con funcion similar al factor de veneno de cobra.
WO2010056399A1 (en) * 2008-11-17 2010-05-20 Incode Biopharmaceutics, Inc. Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors
RU2549468C2 (ru) * 2013-08-09 2015-04-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт нормальной физиологии имени П.К. Анохина" Российской академии медицинских наук (ФГБУ "НИИНФ им. П.К. Анохина" РАМН") Способ определения стабилизации с3-конвертазы классического пути активации комплемента человека
US11903996B2 (en) * 2015-10-07 2024-02-20 David C. Fritzinger Modulators of complement function
US20190016766A1 (en) * 2015-10-07 2019-01-17 Daniel E. Benjamin Use of improved modulators of complement function as cancer therapeutics
CN106472354B (zh) * 2016-10-21 2019-05-31 新希望六和饲料股份有限公司 一种成年鸡用饲料盘
CN106472359B (zh) * 2016-10-21 2019-07-26 新希望六和饲料股份有限公司 一种1-3周龄雏鸡用饲料盘

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661347A (en) 1982-11-12 1987-04-28 Scripps Clinic Cytotoxic compositions
US5714344A (en) 1993-04-07 1998-02-03 Georgetown University Protease-derivatized CVF
WO1994023024A1 (en) 1993-04-07 1994-10-13 Georgetown University Dna encoding cobra c3, cvf1, and cvf2
DE69533359T2 (de) 1994-09-08 2005-07-28 Imutran Ltd. Veränderte menschliche c3-proteine
US6221657B1 (en) 1995-09-08 2001-04-24 Imutran Limited Modified human C3 DNA sequences and vectors
US5922320A (en) 1996-06-14 1999-07-13 Georgetown University Recombinant proCVF
WO2005003159A1 (en) 2003-07-03 2005-01-13 Koeln Johanna Complement depletion using recombinant human c3-derivatives
MXPA06012321A (es) 2004-04-30 2007-04-19 Univ Hawaii Derivados c3 del complemento humano con funcion similar al factor de veneno de cobra.
US20100179092A1 (en) 2006-11-15 2010-07-15 Fritzinger David C Human complement c3 derivatives with cobra venom factor-like function

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017519049A (ja) * 2014-06-12 2017-07-13 ユニヴァーシティ オブ ハワイＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｈａｗａｉｉ 免疫原性を低減するかまたは予防するためのヒト化コブラ毒因子の使用

Also Published As

Publication number Publication date
AU2005240096A1 (en) 2005-11-17
US20080311132A1 (en) 2008-12-18
EP1755658A2 (en) 2007-02-28
US20080234191A1 (en) 2008-09-25
EP1755658A4 (en) 2008-11-05
IL178905A0 (en) 2007-03-08
US8632780B2 (en) 2014-01-21
WO2005107785A3 (en) 2005-12-15
WO2005107785A2 (en) 2005-11-17
KR20070036057A (ko) 2007-04-02
CA2565227A1 (en) 2005-11-17
MXPA06012321A (es) 2007-04-19

Similar Documents

Publication Publication Date Title
US20080234191A1 (en) Human complement C3 derivates with cobra venom factor-like function
JP5833448B2 (ja) セリンプロテアーゼ誘導体および血液凝固疾患の予防または処置における使用
CZ302303B6 (cs) Homodimerní fúzní protein vykazující inhibicní aktivitu na angiogenezi, zpusob jeho produkce, molekula DNA a replikovatelný expresní vektor
JP2008109938A (ja) フォンビルブラント因子（ｖＷＦ）切断酵素
HU218408B (hu) Eljárás protein C- származékok előállítására
JP6884134B2 (ja) 良性前立腺過形成の患者における手術の必要性を低減する方法
JP2001061479A (ja) 血液凝固第ｖｉｉ因子改変体
AU707004B2 (en) Modified proteins
JP4855627B2 (ja) 医薬用途のためのトロンボモジュリン
JP2004105188A (ja) プロテアーゼ−耐性トロンボモジュリン・アナログ
JP2003313199A (ja) コラーゲン誘発血小板凝集抑制剤
EP1088069B1 (en) Angiostatin-binding protein
JP2003500041A (ja) Ｍｅｔｈ１およびｍｅｔｈ２ポリヌクレオチドおよびポリペプチド
US20030207348A1 (en) Polypeptides and polynucleotides encoding same
JPH08511157A (ja) Ｘａファクター阻害活性を有する新規ポリペプチド
JPWO1999014325A1 (ja) 新規Ｆａｓリガンド誘導体
WO1999014325A1 (fr) NOUVEAU DERIVE DU LIGAND Fas
SK121798A3 (en) Native protein of a complement line, a fragment or variant of protein, dna sequence coding a protein, dna construct, a conjugate containing protein, pharmaceutical composition and use of protein
US6835381B1 (en) Methods for modulating angiogenesis by using the anti-angiogenic angiotensin-7 and polynucleotides encoding therefor
CN101014362A (zh) 具眼镜蛇毒因子样功能的人补体c3衍生物
JP2005518801A (ja) 組換えプロテインｃバリアント
CN100425695C (zh) 新型人Rab GTP酶，其编码序列及用途
US6908898B1 (en) Angiogenesis related molecules
US20050244868A1 (en) Ten-M3 polypeptides and polynucleotides and their methods of use
WO2001000664A2 (en) Secreted alpha-helical protein-36

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080404

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080404

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110330

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110614

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120123

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120621